What is the role of antinuclear antibody assays in the evaluation of polymyositis?

Updated: Jan 05, 2021
  • Author: Mythili Seetharaman, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Antinuclear antibody assays are positive in one third of patients with polymyositis and in only 15% of patients with inclusion body myositis. Myositis-specific antibodies include the following [24] :

  • Antisynthetase antibodies (such as anti-Jo-1 antibodies) - Associated with certain clinical features; antisynthetase syndrome may manifest as idiopathic inflammatory myopathy, interstitial lung disease, arthritis, Raynaud phenomenon, fever, and/or mechanic's hands

  • Signal-recognition particle (SRP) antibodies - Approximately 4% of patients with polymyositis have antibodies to signal recognition particles (SRPs), which are associated with acute onset of severe weakness, increased incidence of cardiac involvement, and higher mortality rates.

  • Anti-HMGCR autoantibodies in statin-induced auto immune myopathy [25]

  • Other myositis-specific autoantibodies (MSA) include Mi-2 ,TIF1-γ, anti-p155/p140, anti-CADM-140, NXP2, and SAE, among others [26]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!